Cyclerion Therapeutics (CYCN) Competitors

$3.18 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$3.13 -0.05 (-1.57%)

As of 05/22/2026 07:49 PM Eastern

CYCN vs. TIL, KZR, ESLA, MGX, and ZYBT

Should you buy Cyclerion Therapeutics stock or one of its competitors? MarketBeat compares Cyclerion Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cyclerion Therapeutics include Instil Bio (TIL), Kezar Life Sciences (KZR), Estrella Immunopharma (ESLA), Metagenomi (MGX), and Zhengye Biotechnology (ZYBT). These companies are all part of the "pharmaceutical products" industry.

How does Cyclerion Therapeutics compare to Instil Bio?

Cyclerion Therapeutics (NASDAQ:CYCN) and Instil Bio (NASDAQ:TIL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

Cyclerion Therapeutics has higher revenue and earnings than Instil Bio. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclerion Therapeutics	$2.07M	6.65	-$3.53M	-$1.36	N/A
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A

In the previous week, Cyclerion Therapeutics' average media sentiment score of 0.00 equaled Instil Bio'saverage media sentiment score.

Company	Overall Sentiment
Cyclerion Therapeutics	Neutral
Instil Bio	Neutral

Instil Bio has a net margin of 0.00% compared to Cyclerion Therapeutics' net margin of -170.11%. Instil Bio's return on equity of -39.76% beat Cyclerion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cyclerion Therapeutics	-170.11%	-62.10%	-55.14%
Instil Bio	N/A	-39.76%	-22.38%

Instil Bio has a consensus target price of $66.00, indicating a potential upside of 706.85%. Given Instil Bio's stronger consensus rating and higher probable upside, analysts plainly believe Instil Bio is more favorable than Cyclerion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclerion Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Instil Bio	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

75.6% of Cyclerion Therapeutics shares are owned by institutional investors. Comparatively, 60.6% of Instil Bio shares are owned by institutional investors. 34.3% of Cyclerion Therapeutics shares are owned by company insiders. Comparatively, 47.0% of Instil Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Cyclerion Therapeutics has a beta of 1.8, suggesting that its share price is 80% more volatile than the broader market. Comparatively, Instil Bio has a beta of 1.94, suggesting that its share price is 94% more volatile than the broader market.

Summary

Instil Bio beats Cyclerion Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Cyclerion Therapeutics compare to Kezar Life Sciences?

Kezar Life Sciences (NASDAQ:KZR) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Kezar Life Sciences has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market. Comparatively, Cyclerion Therapeutics has a beta of 1.8, meaning that its stock price is 80% more volatile than the broader market.

67.9% of Kezar Life Sciences shares are owned by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are owned by institutional investors. 10.4% of Kezar Life Sciences shares are owned by insiders. Comparatively, 34.3% of Cyclerion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Cyclerion Therapeutics has higher revenue and earnings than Kezar Life Sciences. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kezar Life Sciences	N/A	N/A	-$56.03M	-$6.17	N/A
Cyclerion Therapeutics	$2.07M	6.65	-$3.53M	-$1.36	N/A

In the previous week, Kezar Life Sciences had 1 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 1 mentions for Kezar Life Sciences and 0 mentions for Cyclerion Therapeutics. Cyclerion Therapeutics' average media sentiment score of 0.00 beat Kezar Life Sciences' score of -0.25 indicating that Cyclerion Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Kezar Life Sciences	Neutral
Cyclerion Therapeutics	Neutral

Kezar Life Sciences currently has a consensus target price of $6.00, suggesting a potential downside of 17.70%. Given Kezar Life Sciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Kezar Life Sciences is more favorable than Cyclerion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kezar Life Sciences	2 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Cyclerion Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Kezar Life Sciences has a net margin of 0.00% compared to Cyclerion Therapeutics' net margin of -170.11%. Kezar Life Sciences' return on equity of -55.42% beat Cyclerion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kezar Life Sciences	N/A	-55.42%	-47.87%
Cyclerion Therapeutics	-170.11%	-62.10%	-55.14%

Summary

Kezar Life Sciences and Cyclerion Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Cyclerion Therapeutics compare to Estrella Immunopharma?

Estrella Immunopharma (NASDAQ:ESLA) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Cyclerion Therapeutics has higher revenue and earnings than Estrella Immunopharma. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Cyclerion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A
Cyclerion Therapeutics	$2.07M	6.65	-$3.53M	-$1.36	N/A

0.4% of Estrella Immunopharma shares are owned by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are owned by institutional investors. 55.1% of Estrella Immunopharma shares are owned by company insiders. Comparatively, 34.3% of Cyclerion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Estrella Immunopharma currently has a consensus price target of $8.00, suggesting a potential upside of 589.66%. Given Estrella Immunopharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Estrella Immunopharma is more favorable than Cyclerion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cyclerion Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Estrella Immunopharma had 1 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 1 mentions for Estrella Immunopharma and 0 mentions for Cyclerion Therapeutics. Estrella Immunopharma's average media sentiment score of 3.00 beat Cyclerion Therapeutics' score of 0.00 indicating that Estrella Immunopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Estrella Immunopharma	Very Positive
Cyclerion Therapeutics	Neutral

Estrella Immunopharma has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, Cyclerion Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the broader market.

Estrella Immunopharma has a net margin of 0.00% compared to Cyclerion Therapeutics' net margin of -170.11%. Estrella Immunopharma's return on equity of 0.00% beat Cyclerion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Estrella Immunopharma	N/A	N/A	-397.36%
Cyclerion Therapeutics	-170.11%	-62.10%	-55.14%

Summary

Estrella Immunopharma beats Cyclerion Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Cyclerion Therapeutics compare to Metagenomi?

Metagenomi (NASDAQ:MGX) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

In the previous week, Metagenomi's average media sentiment score of 0.00 equaled Cyclerion Therapeutics'average media sentiment score.

Company	Overall Sentiment
Metagenomi	Neutral
Cyclerion Therapeutics	Neutral

Metagenomi currently has a consensus target price of $9.00, indicating a potential upside of 566.67%. Given Metagenomi's stronger consensus rating and higher possible upside, analysts plainly believe Metagenomi is more favorable than Cyclerion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Cyclerion Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Metagenomi has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market. Comparatively, Cyclerion Therapeutics has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market.

Cyclerion Therapeutics has a net margin of -170.11% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -51.23% beat Cyclerion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Metagenomi	-384.61%	-51.23%	-36.62%
Cyclerion Therapeutics	-170.11%	-62.10%	-55.14%

75.6% of Cyclerion Therapeutics shares are held by institutional investors. 17.8% of Metagenomi shares are held by insiders. Comparatively, 34.3% of Cyclerion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cyclerion Therapeutics has lower revenue, but higher earnings than Metagenomi. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$25.21M	2.02	-$87.87M	-$2.30	N/A
Cyclerion Therapeutics	$2.07M	6.65	-$3.53M	-$1.36	N/A

Summary

Metagenomi beats Cyclerion Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Cyclerion Therapeutics compare to Zhengye Biotechnology?

Zhengye Biotechnology (NASDAQ:ZYBT) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Zhengye Biotechnology has a beta of -2.47, meaning that its share price is 347% less volatile than the broader market. Comparatively, Cyclerion Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the broader market.

Zhengye Biotechnology has a net margin of 0.00% compared to Cyclerion Therapeutics' net margin of -170.11%. Zhengye Biotechnology's return on equity of 0.00% beat Cyclerion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
Cyclerion Therapeutics	-170.11%	-62.10%	-55.14%

Cyclerion Therapeutics has lower revenue, but higher earnings than Zhengye Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$16.64M	2.47	-$9.98M	N/A	N/A
Cyclerion Therapeutics	$2.07M	6.65	-$3.53M	-$1.36	N/A

75.6% of Cyclerion Therapeutics shares are owned by institutional investors. 34.3% of Cyclerion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cyclerion Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Zhengye Biotechnology's average media sentiment score of 0.00 equaled Cyclerion Therapeutics'average media sentiment score.

Company	Overall Sentiment
Zhengye Biotechnology	Neutral
Cyclerion Therapeutics	Neutral

Summary

Cyclerion Therapeutics beats Zhengye Biotechnology on 5 of the 9 factors compared between the two stocks.

Get Cyclerion Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CYCN vs. The Competition

Export

Metric	Cyclerion Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$13.77M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-2.34	18.74	20.99	25.66
Price / Sales	6.65	323.98	560.30	86.31
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	2.03	7.09	10.41	7.14
Net Income	-$3.53M	$24.45M	$3.57B	$335.98M
7 Day Performance	6.00%	6.38%	6.41%	4.15%
1 Month Performance	8.16%	2.43%	3.55%	2.54%
1 Year Performance	0.82%	62.98%	34.12%	35.06%

Cyclerion Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CYCN Cyclerion Therapeutics	0.8246 of 5 stars	$3.18 flat	N/A	+0.8%	$13.77M	$2.07M	N/A	30
TIL Instil Bio	1.9319 of 5 stars	$8.03 -0.9%	$66.00 +721.9%	-61.1%	$54.44M	N/A	N/A	410	Analyst Upgrade
KZR Kezar Life Sciences	0.7867 of 5 stars	$7.29 flat	$6.00 -17.7%	+85.5%	$53.87M	$7M	N/A	60	High Trading Volume
ESLA Estrella Immunopharma	3.3306 of 5 stars	$1.26 +3.7%	$8.00 +537.5%	+11.5%	$53.55M	N/A	N/A	N/A	Gap Up
MGX Metagenomi	2.4423 of 5 stars	$1.36 +0.4%	$9.00 +564.2%	-16.7%	$50.87M	$25.21M	N/A	236

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CYCN) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cyclerion Therapeutics (CYCN) Competitors

CYCN vs. TIL, KZR, ESLA, MGX, and ZYBT

How does Cyclerion Therapeutics compare to Instil Bio?

Summary

How does Cyclerion Therapeutics compare to Kezar Life Sciences?

Summary

How does Cyclerion Therapeutics compare to Estrella Immunopharma?

Summary

How does Cyclerion Therapeutics compare to Metagenomi?

Summary

How does Cyclerion Therapeutics compare to Zhengye Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYCN vs. The Competition

Cyclerion Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cyclerion Therapeutics (CYCN) Competitors

CYCN vs. TIL, KZR, ESLA, MGX, and ZYBT

How does Cyclerion Therapeutics compare to Instil Bio?

Which has stronger earnings and valuation, CYCN or TIL?

Does the media prefer CYCN or TIL?

Is CYCN or TIL more profitable?

Do analysts rate CYCN or TIL?

Do insiders and institutionals have more ownership in CYCN or TIL?

Which has more risk and volatility, CYCN or TIL?

Summary

How does Cyclerion Therapeutics compare to Kezar Life Sciences?

Which has more risk and volatility, KZR or CYCN?

Do institutionals and insiders hold more shares of KZR or CYCN?

Which has better valuation and earnings, KZR or CYCN?

Does the media refer more to KZR or CYCN?

Do analysts prefer KZR or CYCN?

Is KZR or CYCN more profitable?

Summary

How does Cyclerion Therapeutics compare to Estrella Immunopharma?

Which has higher earnings and valuation, ESLA or CYCN?

Do insiders and institutionals hold more shares of ESLA or CYCN?

Do analysts recommend ESLA or CYCN?

Does the media refer more to ESLA or CYCN?

Which has more risk and volatility, ESLA or CYCN?

Is ESLA or CYCN more profitable?

Summary

How does Cyclerion Therapeutics compare to Metagenomi?

Does the media refer more to MGX or CYCN?

Do analysts recommend MGX or CYCN?

Which has more volatility & risk, MGX or CYCN?

Is MGX or CYCN more profitable?

Do insiders and institutionals believe in MGX or CYCN?

Which has stronger valuation and earnings, MGX or CYCN?

Summary

How does Cyclerion Therapeutics compare to Zhengye Biotechnology?

Which has more risk and volatility, ZYBT or CYCN?

Is ZYBT or CYCN more profitable?

Which has higher earnings and valuation, ZYBT or CYCN?

Do institutionals & insiders believe in ZYBT or CYCN?

Do analysts prefer ZYBT or CYCN?

Does the media refer more to ZYBT or CYCN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYCN vs. The Competition

Cyclerion Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools